MedPath

Effect of a Low-calorie and High-protein Diet Specially Rich in Animal Protein Compared to a Low-calorie and High-protein Diet Specially Rich in Plant Protein on Glucose Metabolism in Subjects With Prediabetes or Type 2 Diabetes and Overweight or Obesity.

Not Applicable
Completed
Conditions
Overweight and Obesity
PreDiabetes
Diabetes Mellitus, Type 2
Interventions
Behavioral: Low-calorie and high-protein diet with the majority of protein coming from animal sources.
Behavioral: Low-calorie and high-protein diet with the majority of protein coming from plant sources.
Registration Number
NCT05456347
Lead Sponsor
Universidad de Zaragoza
Brief Summary

The aim of the study is to explore the effect of a low-calorie diet rich in protein (with a content of 35% of the total calories of the diet), mostly coming from animal sources (75% of total protein), compared to a hypocaloric diet rich in protein (with a content of 35% of the total calories of the diet), mostly coming from plant sources (75% of total proteins), in subjects with prediabetes or type 2 diabetes and overweight or obesity, on body composition, glucose and lipid metabolisms, after 6 months of intervention.

To achieve the objective, a nutritional intervention study is carried out by randomizing participants to: a) a hypocaloric and high-protein diet (35% of total calories), mostly of them coming from animal sources (75% of total protein); b) a hypocaloric and high-protein diet (35% of total calories), mostly of them coming from plant sources (75% of total protein). The study has a total duration of 6 months and include the assessment of clinical, anthropometric, biochemical and lifestyle parameters, at the beginning of the study and after 3 and 6 months of intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Aged between 18 and 80.
  • BMI between 27.5 kg/m2 and 40 kg/m2.
  • Diagnosed as prediabetes or type 2 diabetes according to ADA criteria.
  • Informed consent to be signed.
Exclusion Criteria
  • Taking antidiabetic drugs (except for metformin with stable dose in the previous 6 months).
  • Taking lipid-lowering drugs in unstable dose in the previous 2 months.
  • Taking functional foods (i.e. sterols enriched food) or any other dietary supplement with a significant effect on lipid and glucose metabolism and body weight.
  • Uncontrolled type 2 diabetes (i.e. glycated hemoglobin over 8%)
  • Any disease that could affect study results (i.e. uncontrolled hypothyroidism).
  • Alcohol intake over 30 g/day.
  • Pregnancy or breastfeeding.
  • Any other condition that investigators consider that could interfere with study outcomes.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High-protein animal diet.Low-calorie and high-protein diet with the majority of protein coming from animal sources.Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from animal sources (75% of total protein).
High-protein vegetal diet.Low-calorie and high-protein diet with the majority of protein coming from plant sources.Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from plant sources (75% of total protein).
Primary Outcome Measures
NameTimeMethod
Insulin change.After 3 and 6 months of intervention.

Insulin change assessed by difference in fasting insulin concentration (UI/mL and %) comparing 3 and 6 months visits with respect to baseline.

HOMA-IR change.After 3 and 6 months of intervention.

HOMA-IR change assessed by difference in HOMA-IR concentration (absolute units and %) comparing 3 and 6 months visits with respect to baseline. HOMA-IR is calculated by calculating: \[(fasting glucose (mg/dL) x 0,0555) x fasting insulin (UI/ml)\] ÷ 22,5.

Fat-free mass change.After 3 and 6 months of intervention.

Fat-free mass change assessed by difference in fat free-mass (%) comparing 3 and 6 months visits with respect to baseline.

Visceral fat mass change.After 3 and 6 months of intervention.

Visceral fat mass change assessed by difference in visceral fat mass (kg and %) comparing 3 and 6 months visits with respect to baseline.

Glucose change.After 3 and 6 months of intervention.

Glucose change assessed by difference in fasting glucose concentration (mg/dL and %) comparing 3 and 6 months visits with respect to baseline.

Glycated hemoglobin change.After 3 and 6 months of intervention.

Glycated hemoglobin change assessed by difference in glycated hemoglobin concentration (%) comparing 3 and 6 months visits with respect to baseline.

Body fat mass change.After 3 and 6 months of intervention.

Body fat mass change assessed by difference in fat mass (%) comparing 3 and 6 months visits with respect to baseline.

Secondary Outcome Measures
NameTimeMethod
HDL cholesterol change.After 3 and 6 months of intervention.

HDL cholesterol change assessed by difference in fasting HDL cholesterol concentration (mg/dL and %) comparing 3 and 6 months visits with respect to baseline.

Total cholesterol change.After 3 and 6 months of intervention.

Total cholesterol change assessed by difference in fasting total cholesterol concentration (mg/dL and %) comparing 3 and 6 months visits with respect to baseline.

LDL cholesterol change.After 3 and 6 months of intervention.

Total LDL cholesterol change assessed by difference in fasting LDL cholesterol concentration (mg/dL and %) comparing 3 and 6 months visits with respect to baseline.

Triglycerides change.After 3 and 6 months of intervention.

Triglycerides change assessed by difference in fasting triglycerides concentration (mg/dL and %) comparing 3 and 6 months visits with respect to baseline.

Trial Locations

Locations (1)

Instituto de Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath